Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2016

View Archived Issues

Merck & Co. reports calcitonin gene-related peptide receptor antagonists

Teijin Pharma reports xanthine oxidase inhibitors

HEC Pharm discloses cyclin-dependent kinase inhibitors

Northeastern University has introduced FAAH and MAGL inhibitors

RB launches a Zika Relief Package in response to the global outbreak

FDA issues refusal to file letter regarding Catalyst's NDA for Firdapse

Biotron to test its antiviral compounds for activity against Zika virus

GVN launches Zika Task Force to combat the global Zika outbreak

Eisai and PIQUR enter collaboration agreement to investigate PQR-309 anderibulin combination

Promising preliminary results from T-cell therapy study in hematological cancers

Nanoparticle formulation of AntimiR-21 induces tumor regression in cancer model

Phase I study determines safe dose of lenalidomide in leukemia and lymphoma

Knight Therapeutics supports Medimetriks' acquisition of OPA-15406

Neon Therapeutics licenses peptide-MHC assay technology

FDA grants breakthrough therapy designation for ocrelizumab in primary progressive MS

Interim data suggest potential for RG-101 as backbone therapy for HCV

Helsinn and Mundipharma enter distribution and license agreement for anamorelin in Northern Europe

Aerie reports phase III 12-month safety results for Rhopressa

ImmunoCellular gains access to Stanford's T-cell receptor identification IP

FibroGen presents phase II data for roxadustat in patients with end-stage renal disease

FDA grants priority review to Portola's BLA for andexanet alfa

Kynurenine-3-monooxygenase inhibition as promising new therapeutic strategy for AP-MODS

Takeda's NDS for ixazomib accepted for priority review in Canada

BMS and Dana-Farber Cancer Institute enter immuno-oncology research collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...